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Background. AIDS Clinical Trials Group (ACTG) A5199 compared the neurological and neuropsychological
(NP) effects of 3 antiretroviral regimens in participants infected with human immunodeficiency virus type 1
(HIV-1) in resource-limited settings.
Methods. Participants from Brazil, India, Malawi, Peru, South Africa, Thailand, and Zimbabwe were random-
ized to 3 antiretroviral treatment arms: A (lamivudine-zidovudine plus efavirenz, n = 289), B (atazanavir, emtrici-
tabine, and didanosine-EC, n = 293), and C (emtricitabine-tenofovir-disoproxil fumarate plus efavirenz, n = 278)
as part of the ACTG PEARLS study (A5175). Standardized neurological and neuropsychological (NP) screening
examinations (grooved pegboard, timed gait, semantic verbal fluency, and finger tapping) were administered every
24 weeks from February 2006 to May 2010. Associations with neurological and neuropsychological function were
estimated from linear and logistic regression models using generalized estimating equations.
Results. The median weeks on study was 168 (Q1 = 96, Q3 = 192) for the 860 participants. NP test scores
improved (P < .05) with the exception of semantic verbal fluency. No differences in neurological and neuropsycho-
logical functioning between treatment regimens were detected (P > .10). Significant country effects were noted on
all NP tests and neurological outcomes (P < .01).
Conclusions. The study detected no significant differences in neuropsychological and neurological outcomes
between randomized ART regimens. Significant improvement occurred in neurocognitive and neurological func-
tioning over time after initiation of ARTs. The etiology of these improvements is likely multifactorial, reflecting
reduced central nervous system HIV infection, better general health, and practice effects. This study suggests that
treatment with either of the World Health Organization –recommended first-line antiretroviral regimens in
resource-limited settings will improve neuropsychological functioning and reduce neurological dysfunction.
Clinical trials registration. NCT00096824.
Received 9 December 2011; accepted 11 May 2012; electronically published 1
June 2012.
Correspondence: Kevin R. Robertson, Department of Neurology, University of
North Carolina, 2128 Physician Office Building, 170 Manning Drive, Chapel Hill,
NC 27599-7025 (kevinr@neurology.unc.edu).
Clinical Infectious Diseases 2012;55(6):868–76
© The Author 2012. Published by Oxford University Press on behalf of the Infectious
Diseases Society of America. All rights reserved. For permissions, please e-mail:
journals.permissions@oup.com.
DOI: 10.1093/cid/cis507
868 • CID 2012:55 (15 September) • Robertson et al
Currently, the greatest burden of the human immunodeficien-
cy virus type 1 (HIV-1) epidemic is in resource-poor, develop-
ing parts of the world where the majority of new infections
occur [1]. An important component of this epidemic includes
its effects on the central and peripheral nervous systems (CNS
and PNS), through opportunistic infections and by more
direct effects of HIV-1. Considerable evidence exists to suggest
the local effects of viral and immune factors in the CNS and
PNS underlie the damage done [2].
The spectrum of HIV-related CNS diseases is grouped
under HIV-associated neurological disorders (HAND) [3] and
includes the more severe form of HIV-associated dementia
(HAD), the less severe but more prevalent HIV-associated
minor neurocognitive disorder (MND), and asymptomatic
neurocognitive impairment (ANI) [4–8]. In the era prior to
highly active antiretroviral therapy (HAART), as many as 80%
of people who died from AIDS in the United States had
autopsy evidence of CNS injury attributable to HIV-1 regard-
less of whether there had been clear manifestations of HAD
during life [9].
Because little is known about the impact of antiretroviral
treatment on neuropsychological functioning and neurological
dysfunction in HIV-1–infected people in resource-limited set-
tings, this study examined the neurological and neuropsycho-
logical effects of 3 randomly assigned antiretroviral regimens,
including a direct comparison of 2 regimens recommended by
the World Health Organization (WHO) for first-line treat-
ments of HIV-1 in resource-limited setting (efavirenz with




A5199, the International Neurological Study (Clinicaltrials.
gov, NCT00096824) enrolled solely from ACTG A5175, a ran-
domized treatment trial of antiretroviral efficacy and safety.
The international ACTG sites that participated in A5199 were
located in Rio de Janeiro, Brazil; Porto Alegre, Brazil;
Chennai, India; Pune, India; Blantyre, Malawi; Lilongwe,
Malawi; Lima, Peru; Johannesburg, South Africa; Durban,
South Africa; Chiang Mai, Thailand; and Harare, Zimbabwe.
Procedures
Human subjects study reviews and approvals by local and
country specific review boards were obtained at each site prior
to study initiation, and informed consent was obtained prior
to study participation. The National Institutes for Health
(NIH), National Institute for Allergy and Infectious Diseases
(NIAID), Division of AIDS (DAIDS), and Multinational Data
Safety and Monitoring Board monitored the study at intervals
to ensure safe and appropriate conduct. Standardized training
on administration of the neurological and neuropsychological
screening examinations was conducted. Rigorous data moni-
toring at data entry through computerized range checks, with
follow-up data cleaning through multiple queries and replies,
was conducted throughout the study. Implausible values were
queried, and confirmed or corrected at intervals.
Participants
Participants were a subset of ACTG A5175, a randomized an-
tiretroviral treatment trial (ClinicalTrials.gov, NCT00084136).
Eligible subjects for A5175 were men and women 18 years or
older who had documented HIV-1 infection, CD4+ lympho-
cytes less than 300 cells/mm3, Karnofsky performance score
greater than or equal to 70, and no more than 7 days of cumu-
lative prior antiretroviral therapy prior to study entry. Partici-
pants were excluded from participation in the study if they
had any active severe psychiatric illness, active drug or alcohol
abuse or dependence, serious illness and/or hospitalization
within 14 days of study entry, or any other condition that, in
the opinion of the site investigator, would compromise the
person’s ability to participate in the study, adhere to study re-
quirements, or confound the analysis or interpretation of the
results of the study.
Treatment Arms
The parent study, A5175, was a phase IV, randomized, open-
label, 3-arm, antiviral efficacy trial designed to evaluate 3
antiretroviral regimens for treatment-naive HIV-infected par-
ticipants: 1 regimen of 2 nucleoside reverse transcriptase
inhibitors (NRTIs) plus an HIV-1 protease inhibitor (PI) and
2 regimens of 2 NRTIs plus a nonnucleoside reverse transcrip-
tase inhibitor (NNRTI). Arm A consisted of coformulated
lamivudine (3TC)/zidovudine (ZDV) 150 mg/300 mg PO BI-
Defavirenz (EFV) 600 mg PO QHS, arm B was emtricitabine
(FTC) 200 mg PO QD plus atazanavir (ATV) 400 mg PO QD
plus didanosine enteric-coated (ddI-EC) 400 mg PO QD for
participants who weighed ≥60 kg or ddI-EC 250 mg PO QD
for participants who weighed <60 kg, and arm C was cofor-
mulated FTC/tenofovir (TDF) 200 mg/300 mg PO QHS plus
EFV 600 mg PO QHS. If a participant had treatment failure,
defined as a viral load >1000 copies/mL on study, they entered
step 2: those on arm A with treatment failure went on to arm
2A, which consisted of 2 NRTIs plus PI(s); while those on
arm B who had treatment failure went on to arm 2B which
consisted of 2 NRTIs plus EFV; and those on arm C who had
treatment failure went on to arm 2C, which consisted of 2
NRTIs plus PI(s).
The Data and Safety Monitoring Board (DSMB) review of 6
May 2008 concluded that arm B FTC plus ATV plus ddI was
inferior to 3TC-ZDV plus EFV and should not be
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recommended for initial therapy in antiretroviral-naive indi-
viduals; arm B was discontinued, and participants offered the
option to change regimens in Step 3 to track changes in anti-
retroviral regimens.
Standardized neurological and neuropsychological (NP)
screening examinations (grooved pegboard, timed gait, seman-
tic verbal fluency, and finger tapping) were administered every
24 weeks from February 2006 to May 2010. The neuropsycho-
logical tests were chosen on the basis of prior experience in
clinical trial and cohort studies in the United States, with par-
ticular care taken to keep the battery short and minimizing
language- and culture-specific items [11, 12]. Although neuro-
psychological tests are used for assigning impairment ratings
or for diagnoses of HAND, appropriate normative data do not
exist to make these assessments in this study.
The neurological examination included a neurological
history and symptom review and cognitive, motor, sensory
and reflex assessments, and was conducted primarily by physi-
cians, less often by midlevel clinicians such as nurse practi-
tioners. A study-specific diagnosis form was completed for
each participant and included HAD, MND, and peripheral
neuropathy, in addition to CNS opportunistic infections. The
diagnosis of diffuse CNS-disease related to HIV was catego-
rized as MND if impairment was rated as subclinical or equiv-
ocal, and as HAD if it was categorized mild, moderate, or
severe, on the basis of the severity levels in the ADC Staging
criteria as follows. Subclinical or equivocal was defined as
either minimal or equivocal symptoms or motor dysfunction
characteristic of ADC, or mild signs (snout response, slowed
extremity movements) but without impairment of work or ca-
pacity to perform activities of daily living (ADL). Mild was
defined as unequivocal evidence of functional intellectual or
motor impairment but able to perform all but the more de-
manding aspects of work or ADL. Moderate was defined as
cannot work or maintain the more demanding aspects of daily
life but able to perform basic activities of self-care. Severe was
defined as major intellectual incapacity (cannot follow news
or personal events, cannot sustain complex conversation, con-
siderable slowing of all output) or motor disability.
Statistical Analyses
Linear and logistic regression models using generalized esti-
mating equation (GEE) with an autoregressive correlation
structure (for within-patient correlation) were constructed to
assess the treatment effects as well as the associations of other
covariates with neuropsychological test scores and neurologi-
cal outcomes which included overall neurological examination
abnormality, PNS, focal or diffuse CNS abnormality. The co-
variates included in the model were country, randomized
treatment, baseline HIV-1 RNA stratum (<100 000 vs
≥100 000 copies/mL), screening CD4 stratum (<50, 50–99,
100–199, 200–249, and 250–299 cells/mm3) , baseline neuro-
cognitive test scores, age, sex, and years of education. Al-
though CD4+ cell nadir was not available, but because these
participants were treatment naive, current CD4+ cell count
likely approximates the nadir. A second model used the same
covariates as above plus current HIV-1 RNA, and current
CD4 to estimate the associations of current CD4 and current
HIV-1 RNA on neurological and neuropsychological func-
tions. Parameters were interpreted for a 10-year change in age,
a 50-unit change in CD4 count, a 4-year change in education,
and a 1 log change in entry plasma HIV-1 RNA. CD4 count
and entry plasma HIV-1 RNA were used as continuous vari-
ables in modeling. HIV-1 RNA value at study follow-up was
dichotomized into detectable vs undetectable using the lower
assay detection limit of 400 copies/mL, below which viral
load levels were censored. In each case, 95% confidence
intervals (CIs) are used to estimate the covariate effects. Leten-
dre has developed a ranking system to assess CNS penetra-
tion-effectiveness (CPE) of antiretrovirals based on chemical
properties, CSF to plasma concentrations, and effectiveness in
clinical studies. Highly penetrating drugs receive a rank of 4,
high intermediate drugs a 3, low intermediate drugs a 2, and
low penetrating drugs a 1. For the total CPE score in a regimen,
the rankings of each individual agent are summed [13]. Treat-
ment arm A had CPE of 9; treatment arms B and C had CPE
scores of 7.
Forest plots were generated to summarize associations. Lon-
gitudinal plots were used to display temporal trends. All sig-
nificance testing was performed at the .05 level, a trend for
significance was defined as P > .05 and P < .15 level, and no
adjustments for multiple testing or multiple comparisons were
used. All reported P values are 2-sided.
RESULTS
Demographics
The baseline results for A5199 have been reported elsewhere [14],
but a brief summary of the demographics for the cohort is
presented here (see Table 1). The total enrollment was 860
participants: 452 (53%) females and 408 (47%) males. The
median age was 34 years, and the median educational level
was 10 years (Q1-7, Q3-12). By country, there were 161 par-
ticipants in Brazil, 184 in India, 133 in Malawi, 62 in Peru,
167 in South Africa, 73 in Thailand, and 80 in Zimbabwe. The
parent study enrolled in both US and international sites, with
a total of 1261 enrolled into A5175 at the A5199 participating
sites, and 401 not participating in A5199. There were no sig-
nificant differences in sex, race, ethnicity, age, intravenous
drug use, CD4 count, and plasma HIV RNA between demo-
graphics between the A5175 and A5199 participants.
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Treatment Arm Comparisons
No significant differences existed between the 3 randomized
treatment arms in neuropsychological or neurological out-
comes over time. Therefore, there were no observed differenc-
es related to neuropsychological or neurological functioning
over time between CPE score for these regimens. Treatment
arm A (CPE = 9) vs arm C (CPE = 7) and treatment arm A vs
arm B (CPE = 7) were not different from one another in neu-
rological and neuropsychological outcome.
Longitudinal Follow-up
Median follow-up was 168 weeks on study (Q1 = 96, Q3 = 192,
see Figure 1). As expected, there were significant increases in
CD4+ lymphocyte counts and significant decreases in plasma
HIV-1 RNA over the course of the study. Overall neurological
abnormality and neuropathy improved over time with initiation
of antiretroviral treatment (see Figure 2). For follow-up on study,
at week 24 there were 860 participants, 857 at week 48, 783 at
week 72, 666 at week 96, 624 at week 120, 620 at week 144, 546
at week 168, 342 at week 192, and 62 at week 216, whose data
were included when neurocognitive functions were assessed. Sig-
nificant improvements were seen in all the neuropsychological
test scores over weeks on study after antiretroviral treatment ini-
tiation (P < .05) with exception of semantic verbal fluency. These
improvements were sustained over 3 years of follow-up (see
Figure 3 for example and online supplemental figures).
Country
As expected, there was significant variation in neuropsycho-
logical performance across countries (see Figure 4 as an



















CD4 count, cells/mm3 Median 172.5 183 198 178 167 157 125 170.5
Q1, Q3 97.5, 232.0 75, 257 136, 236 122, 232 88, 234 100, 216 37, 177 98.5, 217.5
Log10 plasma HIV-1
RNA, copies/mL
Median 5.0 5.2 5.1 4.8 4.8 5.2 5.0 5.2
Q1, Q3 4.5, 5.5 4.7, 5.6 4.5, 5.5 4.4, 5.2 4.2, 5.1 4.6, 5.7 4.6, 5.3 4.6, 5.6
Sex Male 408 102 102 39 37 60 37 31
Female 452 59 82 94 25 107 36 49
Age Median 34 36 33 31 33 34 33 36
Education level Median 10 9 9 8 12.5 11 10 11
Q1, Q3 7, 12 6, 11 6, 11 4, 11 11, 14 9, 12 6, 15 8.5, 12.5
Figure 1. Consort diagram of participants in the study.
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Figure 2. Improvements in neurological disease, human immunodeficiency virus RNA, and CD4 cell counts over time. *Test scores improved at each
follow-up visit compared to baseline (each P value < .01 by Wilcoxon signed-rank test). Abbreviations: CNS, central nervous system; HIV, human
immunodeficiency virus.
Figure 3. Median (Q1, Q3) changes in grooved pegboard from baseline. *Test scores improved at each follow-up visit compared to baseline (each
P value < .01 by Wilcoxon signed-rank test). Abbreviations: Dom, dominant; Non-Dom, non-dominant.
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example and online supplemental figures). India was chosen
as the reference for the following comparisons controlling for
covariates of age, sex, education, baseline functioning, screen-
ing RNA stratum, screening CD4 count, time, and treatment
arm. The South American countries and Thailand performed
better on grooved pegboard over time. Malawi and South
Africa performed poorer, whereas South America and Zimba-
bwe performed better in semantic verbal fluency over time.
Peru, South Africa, Thailand, and Zimbabwe had better per-
formance on timed gait over time. Malawi and Peru per-
formed worse, whereas Zimbabwe had better performance on
finger tapping over time. Substantial country variation was
also seen with respect to overall neurological abnormality.
South Africa was the reference in the comparisons. There was
higher overall abnormality rate in Thailand and Zimbabwe
and lower rate in India and Peru over time.
Correlations With Neurological and Neuropsychological
Performance
Higher baseline neuropsychological scores were associated
with better future neuropsychological performance on all tests.
Increasing education was associated with better performance
on finger tapping and semantic verbal fluency, and trends
existed for grooved pegboard and timed gait (P < .15). Increas-
ing age was significantly associated with decreased perfor-
mance on grooved pegboard dominant/nondominant and
timed gait but not for finger tapping and semantic verbal
fluency. Similar to the neuropsychological findings, older age
was associated with higher odds of overall neurologic abnor-
mality for each 10-year increment (odds ratio [OR], 1.38 [95%
CI: 1.18–1.62], P < .001), whereas higher education was associ-
ated with lower odds of overall neurological abnormality for
each 4-year increment (OR, .82 [95% CI: .69–.97], P < .05).
Lower screening RNA stratum was related to better perfor-
mance over time in grooved pegboard dominance with similar
trends for grooved pegboard nondominance, verbal fluency,
and timed gait (P < .15). A higher screening CD4 count was
related to better performance over time in timed gait, and
trends were seen for better performance over time in grooved
pegboard and finger tapping (P < .15). Compared to partici-
pants without HAD and MND, those given a diagnosis of
HAD or MND on the basis of the neurological exam had
trends for poorer performance on the neuropsychological tests
over time (Table 2).
DISCUSSION
This is the first clinical trial to our knowledge of the impact of
randomized antiretroviral regimens on neuropsychological
and neurological function in HIV-positive participants across
diverse international resource-limited settings.
No significant differences were seen in neurocognitive or
neurological functioning between the randomized treatment
arms. Importantly, this provides a comparison of WHO first-
Figure 4. Country differences in grooved pegboard dominant hand. *P-values for each comparison with India: Brazil (P = .01), Malawi (P = .49), Peru
(P < .01), South Africa (P = .83), Thailand (P < .01), and Zimbabwe (P = .27). India was chosen as the reference country due to having the largest sample
size. Abbreviations: CI, confidence interval; Dom, dominant.
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line recommended treatment regimens for resource-limited
settings (3TC/ZDV + EFV vs FTC/TDF + EFV) [10]. The
amount of the neuropsychological and neurological improve-
ments did not differ between these 2 arms, consistent with the
virological and immunological improvements in the primary
study. In addition, this provided evidence that the higher CPE
value in arm A (3TC/ZDV + EFV) vs arm C (FTC/TDF +
EFV) did not provide additional neurological or neurocogni-
tive benefit.
Sustained antiretroviral therapy improved neuropsychologi-
cal functioning and reduced overall neurological abnormality
in treatment-naive HIV-positive participants. This improve-
ment was sustained over more than 3 years of follow-up. This
is an important finding with substantial clinical relevance for
individuals living with HIV, especially because the overwhelm-
ing majority of the disease burden is in resource-limited set-
tings. The choice of regimen, whether an NNRTI or a PI on a
2 NRTI backbone, or whether that regimen is dosed once or
twice daily appeared less important for improving neuropsy-
chological functioning than initiating and maintaining suc-
cessful antiretroviral treatment.
In the developed world, several studies have shown that
ART was associated with improvement in cognitive and pe-
ripheral nervous system function [15–18]. Prior to the current
study, we did not know whether these neurological benefits
would be seen in HIV-infected patients in resource-limited
settings. As has been seen in studies from the United States
and Europe, we found that neuropsychological function im-
proved and neurological abnormalities were less common
after antiretroviral treatment.
There was substantial variation in neurological and neuro-
psychological outcomes by country in this study. This country
variation was not unexpected, and a primary reason the study
was conducted in such diverse settings was to assess the
degree of such variability. Prior studies have found country
differences in neurological and neuropsychological outcomes
including resource-limited settings [19–23]. One important
factor in our study was differences in education across sites. In
addition, the differences between sites could be due to varia-
tion in the administration of the neuropsychological tests and
neurological examination. We minimized this possibility by
conducting on-site and centralized training sessions. Different
HIV-1 subtypes likely predominated in the individual coun-
tries in which this study was conducted, and those differences
may have contributed to the differences in neurological or
neuropsychological performance that we observed. For
example, Sacktor et al [20] documented that among a group
of HIV-infected individuals in Uganda, those infected with
subtype D had a greater prevalence of HIV-associated neuro-
logical disease than those with subtype A.
This study found a low level of HAD or MND over time,
likely because the participants were fairly healthy. A Karnof-
sky score of 70 or better was an inclusion criterion, thus se-
lecting for individuals who were less likely to have
neurological abnormalities. In addition, sites were encouraged
to recruit participants who they thought would be compliant
and adhere to study procedures, potentially leading to a bias
toward enrolling a healthier study population with less neuro-
logical impairment.
Improvement in neuropsychological test performance was
seen across the study. In part, this could be due to practice or
learning effects, but several arguments can be made that the
improvements were not solely or substantially due to practice
effect. We included timed gait, a test that consists of walking.
Walking is an overlearned task that is resistant to practice or
learning effects. Timed gait improved over the study, consistent
with ART-associated improvement. In addition, practice and
learning effects likely had little effect on neurological examina-
tion findings, and these improved over the course of the study.
However, clinicians were not blinded to the antiretroviral treat-
ment arms, ratings, which could have biased the neurological
assessments. Although there were no direct correlations
between neuropsychological or neurological outcomes and
higher CD4+ cell counts or lower plasma HIV RNA, these sys-
temic disease markers improved over the study as did neurolog-
ical and neuropsychological functioning.
Table 2. Association of Current HIV-Associated Dementia/Minor Neurocognitive Disorder With Each Neuropsychological Test
Test Estimate 95% CI P
Grooved pegboard dominant, s 10.12 (−.069 to 20.30) .05
Grooved pegboard nondominant, s 6.45 (−1.16 to 14.07) .10
Semantic verbal fluency, no. of words − 0.62 (−1.41 to− .17) .13
Timed gait, s 0.92 (.19–1.65) .01
Finger tap dominant, no. of taps − 2.02 (−4.24 to− .19) .07
Finger tap nondominant, no. of taps −1.77 (−3.26 to −.27) .02
Association of neuropsychological test scores in subjects without and with minor neurocognitive disorder/HIV-associated dementia on study.
Abbreviations: CI, confidence interval; s, seconds to complete.
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HIV-associated cognitive impairment has substantial
impact on even the simplest activities of daily living. The
burden of neurological disease on families and communities is
substantial, with loss of productivity and income for the diag-
nosed, but also for those who take the primary responsibility
as caretakers. In resource-limited settings with high rates of
HIV infection, the toll has been devastating [24–26]. This
study suggests that successful antiretroviral therapy will
improve neuropsychological functioning and reduce overall
neurological abnormality in naive HIV-positive participants
and is an important reason for increasing and sustaining
access to therapy in resource-limited settings.
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